medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2019, Number 3

<< Back Next >>

Rev Mex Oftalmol 2019; 93 (3)

Periocular capillary hemangioma in 2018: natural course, indications for treatment and therapeutic options

Fleitman-Broder C

Language: Spanish
References: 24
Page: 142-148
PDF size: 303.04 Kb.


ABSTRACT

Capillary hemangiomas are one of the most common benign orbital and eyelid childhood tumors. Many of these tumors do not require treatment because they regress spontaneously without leaving sequelae; however, treatment is necessary in many cases, such as amblyogenic or eye-threatening lesions. Treatment of this kind of lesions has evolved from surgical excision to laser and steroids, all of them successful in different ways and with a range of side effects. In the last few years treatment has been revolutionized due to a casual finding made by Leaute-Labreze et al. Nowadays we use beta-blockers that have proved to be highly effective and with a much safer profile than previously used drugs. Several case reports have shown success by treating these lesions with topical beta-blockers. With this safer and more effective treatment, we can currently treat this lesions that in the past were just kept under observation, diminishing the cosmetic sequelae and the social stigma of patients having such lesions in their facial area.


REFERENCES

  1. Hoyt C, Taylor D. Pediatric Ophthalmology and Strabismus. 3rd ed. Philadelphia: Elsevier Saunders; 2005.

  2. Nelson LB, Olitsky SE. Harley’s Pediatric Ophthalmology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.

  3. Shields JA, Shields CL. Eyelid, Conjunctival, and Orbital Tumors. 2nd ed. Philadelphia: Lippincot Williams & Wilkins; 2008.

  4. Fabian ID, Ben-Zion I, Samuel C, Spierer A. Reduction in astigmatism using propranolol as first-line therapy for periocular capillary hemangioma. Am J Ophthalmol. 2011;151(1):53-8.

  5. Ni N, Wagner RS, Langer P, Guo S. New Developments in the Management of Periocular Capillary Hemangioma in Children. J Pediatr Ophthalmol Strabismus. 2011;48(5):269-76.

  6. Frank RC, Cowan BJ, Harrop AR, Astle WF, McPhalen DF. Visual development in infants: visual complications of periocular hemangiomas. J Plast Reconstr Aesthet Surg. 2010;63(1):1-8.

  7. North PE, Waner M, Mizeracki A, Mihm JMC. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31(1):11-22.

  8. Barnes CM, Huang S, Kaipainen A, Sanoudou D, Chen EJ, Eichler GS, et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Nat Acad Sci USA. 2005;102(52):19097-102.

  9. Zimmermann AP, Wiegand S, Werner JA, Eivazi B. Propranolol therapy for infantile haemangiomas: Review of the literature. Int J Pediatr Otorhinolaryngol. 2010;74(4):338-42.

  10. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe haemangiomas of infancy. N Engl J Med. 2008;358(24):2649-51.

  11. Gawley SD, Bingham EA, McGinnity G. Visual outcomes of treated periocular capillary haemangiomas in childhood: a10-year review. Acta Ophthalmol. 2011;89(4):396-401.

  12. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104(6):1616-23.

  13. Arneja JS, Mulliken JB. Resection of amblyogenic periocular hemangiomas: indications and outcomes. Plast Reconstr Surg. 2010;125(1):274-81.

  14. Greinwald JH Jr, Burke DK, Bonthius DJ, Bauman NM, Smith RJ. An update on the treatment of hemangiomas in children with interferon alfa- 2a. Arch Otolaryngol Head Neck Surg. 1999;125(1):21-7.

  15. Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013;131(1):99-108.

  16. Ni N, Langer P, Wagner R, Guo S. Topical Timolol for Periocular Hemangioma: Report of Further Study. Arch Ophthalmol. 2011;129(3):373-9.

  17. Haider KM, Plager DA, Neely DE, Eikenberry J, Haggstrom A. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. JAAPOS. 2010;14(3):251-6.

  18. Guo S, Ni N. Topical Treatment for Capillary Hemangioma of the Eyelid Using β-Blocker Solution. Arch Ophthalmol. 2010;128(2):255-6.

  19. Semkova K, Kazandjieva J. Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study. Clin Exp Dermatol. 2013;38(2):143-6.

  20. Jha AK, Mallik SK, Raihan M. Topical ophthalmic solution in infantile hemangioma. J Postgrad Med. 2012;58(2):163-5.

  21. Moehrle M, Léauté-Labrèze C, Schmidt V, Röcken M, Poets CF, Goelz R. Topical Timolol for Small Hemangiomas of Infancy. Pediatr Dermatol. 2013;30(2):245-9.

  22. Calvo M, Garcia-Millán C, Villegas C, Fueyo-Casado A, Burón I. Topical timolol for infantile hemangioma of the eyelid. Int J Dermatol. 2013;52(5):603-4.

  23. Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. A Controlled Study of Topical 0.25% Timolol Maleate Gel for the Treatment of Cutaneous Infantile Capillary Hemangiomas. Ophthal Plast Reconstr Surg. 2012;28(2):103-6.

  24. Oranje AP, Janmohamed SR, Madern GC, de Laat PC. Treatment of Small Superficial Haemangioma with Timolol 0.5% Ophthalmic Solution: A Series of 20 Cases. Dermatology. 2011;223(4):330-4.




2020     |     www.medigraphic.com